|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||35.83 - 36.30|
|52 Week Range||31.67 - 39.43|
|PE Ratio (TTM)||10.30|
|Earnings Date||Apr 30, 2018 - May 4, 2018|
|Forward Dividend & Yield||1.36 (3.81%)|
|1y Target Est||40.25|
What Should Vanda Pharmaceuticals Investors Be Watching in 2018? Investors can expect a slew of critical developments from Vanda Pharmaceuticals (VNDA) in 2018. It expects to begin a tradipitant Phase 3 study in the first half of 2018 for atopic dermatitis and publish results from the tradipitant clinical study for the treatment of gastroparesis by the end of fiscal 2018.
What Should Vanda Pharmaceuticals Investors Be Watching in 2018? Vanda Pharmaceuticals (VNDA) is a biopharmaceutical company with a focus on developing and commercializing innovative therapies. Vanda Pharmaceuticals has adopted a five-pronged business strategy with a goal of becoming a leading global biopharmaceutical company.
Pfizer Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted positive opinions recommending that two Pfizer hematology medicines be granted marketing authorizations in the European Union .
Pfizer Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended against expanding use of SUTENT® to include the adjuvant treatment of adult patients at a high risk of recurrent renal cell carcinoma following nephrectomy .
This could indicate that investors who seek to profit from falling equity prices are not currently targeting PFE. Over the last one-month, outflows of investor capital in ETFs holding PFE totaled $8.65 billion.
The young biotech firm Solid Biosciences Inc (NASDAQ: SLDB ) secured two Buy ratings Tuesday and another Wednesday. The Rating Chardan Capital analyst Gbola Amusa initiated Solid Biosciences with a Buy ...
Novartis: What Are the Major Growth Drivers for 2018? Aimovig, which is Novartis’s (NVS) investigational migraine prophylaxis therapy, is currently under review by the FDA and the European Medicines Agency (or EMA). More than 10.0% of the adults in the world suffer from migraine.
Vasant Narasimhan, the 41-year-old chief executive at Novartis AG, is vowing data science and digital technologies will revolutionize the company’s drug-development pipeline.